Novo Nordisk's oral semaglutide gets EU approval for heart related treatment of type 2 diabet
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
We are taking Ayurveda to the world as a sustainable healthcare solution: Union Minister Prataprao Jadhav
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Subscribe To Our Newsletter & Stay Updated